Der var ingen væsentlig forskel i procentdelen af patienter i alderen 65 år eller derover i lenalidomid/ dexamethason - og placebo/ dexamethason- grupperne.
The percentage of patients aged 65 or over was not significantly different between the lenalidomide/dexamethasone and placebo/dexamethasone groups.